Photocure: Hexvix/Cysview demonstrates long term benefit
Results from 5.5 year follow up of recurrence of bladder cancer
Photocure announced the results from a 5.5 year follow up of recurrence in patients with Non Muscle Invasive Bladder Cancer( NMIBC) showing a long term benefit of the use of Hexvix compared to patients who received white light cystoscopy alone. After a follow-up up period up to 5.5 years, the number of patients who have experienced recurrence of their bladder cancer is lower, and the time it takes before the recurrence occurs is longer when they had Hexvix-guided fluorescence cystoscopy.
This clinical study includes retrospective follow up from 526 patients included in a prospective randomized Phase III trial in 28 centers in EU and North America. The results from this Phase III study were published in Journal of Urology November 2010 by Stenzl et al. In this 5.5 year follow- up study data were collected related to additional bladder cancer recurrences after they had completed the prospective Phase III trial.
The results (Intention to Treat) showed that fewer patients who received Hexvix experienced recurrence of their bladder cancer compared to patients who did not receive Hexvix, e.g. 38% in the Hexvix group versus 31.8% in the group that did not receive Hexix had no recurrence during the 5.5 year observation period. A statistically significant difference was observed between the recurrence free survival curves, p=0.04.
Other news from the department research and development
